【摘要】 偏头痛是一种临床常见、病残性较强的原发性头痛，给全球带来沉重的疾病与经济负担。由于传统口服预防性药物疗效欠佳、不良反应明显，导致患者依从性差，临床上存在巨大的未满足需求；靶向降钙素基因相关肽（CGRP）通路单克隆抗体药物为偏头痛的预防性治疗带来了新的选择。本文旨在系统梳理和总结抗CGRP及其受体单克隆抗体在偏头痛预防性治疗中的最新研究进展，涵盖其作用机制、关键临床试验证据和真实世界应用、安全性和卫生经济学价值等，为临床医师和相关专业人员提供全面、前沿的循证参考。更多还原

【Abstract】 Migraine is a common and highly disabling primary headache, imposing a heavy disease and economic burden worldwide. Although various traditional oral prophylactic medications exist, their limited efficacy and frequent adverse reactions lead to poor patient adherence, resulting in a large unmet clinical need. Calcitonin gene-related peptide(CGRP) plays a core role in the initiation and development of migraine, and monoclonal antibodies targeting the CGRP pathway offer a novel option for migraine prophylaxis. This review aims to systematically summarize the latest research advances of anti-CGRP and anti-CGRP receptor monoclonal antibodies in the preventive treatment of migraine, covering their mechanisms of action, key clinical trial evidence, real-world applications, safety profiles, and health economic value, so as to provide clinicians and related professionals with a comprehensive, up-to-date evidence-based reference.更多还原